On August 10, INNOVENT BIO rose 3.06% in regular trading, trading at 97.7 HKD/share, with turnover of HKD 743 million. The stock continued its upward momentum driven by a combination of strong first-half earnings and research pipeline catalysts.

The company recently disclosed that first-half product revenue exceeded RMB 8.2 billion, representing year-over-year growth of over 55%, significantly surpassing market expectations of RMB 6.9 billion. Second-quarter product revenue alone topped RMB 4.3 billion, up approximately 60% YoY. Goldman Sachs raised its target price to HKD 111.68, BOCOM International set a target of HKD 118, and Citi reaffirmed its HKD 115 target, all maintaining Buy ratings. The growth was driven by flagship products and broader market penetration of five tyrosine kinase inhibitor therapies included in the National Reimbursement Drug List.

Additionally, the company announced that its Ibi363 combined with bevacizumab key registration study for advanced colorectal cancer has completed first patient enrollment, providing further R&D pipeline catalysts reinforcing positive sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)